We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+64.04%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.61B
AUM Growth
+$301M
Cap. Flow
-$35.3M
Cap. Flow %
-1.36%
Top 10 Hldgs %
53.33%
Holding
82
New
6
Increased
24
Reduced
27
Closed
10
Avg Time Held
2.5 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.6 years

Top Buys

Rank Stock Value
1
IMGN icon
Immunogen Inc
IMGN
+$114M
2
KRYS icon
Krystal Biotech
KRYS
+$66.7M
3
CTLT icon
CATALENT, INC.
CTLT
+$24.2M
4
COGT icon
Cogent Biosciences
COGT
+$23.6M
5
ZBH icon
Zimmer Biomet
ZBH
+$20.6M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$102M
2
ARGX icon
argenx
ARGX
+$48.6M
3
OSH
Oak Street Health, Inc.
OSH
+$41.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$31.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.11%
2 Industrials 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CTSO icon
76
Cytosorbents Corp
CTSO
$9.74M
– –
-9,082
Closed -$612K –
ILMN icon
77
Illumina
ILMN
$41.2B
– –
-34,434
Closed -$7.79M –
SRPT icon
78
Sarepta Therapeutics
SRPT
$1.88B
– –
-231,595
Closed -$31.9M –
STLN icon
79
Starling Oncology
STLN
$696M
– –
-318,082
Closed -$216K –
ISEE
80
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-4,205,206
Closed -$102M –
TCRR
81
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-658,336
Closed -$988K –
OSH
82
DELISTED
Oak Street Health, Inc.
OSH
– –
-1,061,295
Closed -$41.1M –
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2023 Portfolio in Review

As of Q2 2023, Redmile Group held 82 positions worth $2.61B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group's Q2 2023 filing shows 6 new, 24 increased, 27 reduced and 10 closed positions. Its largest new stake was Cogent Biosciences: 2,053,333 shares worth $24.3M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $102M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Industrials.

  • Redmile Group's largest Q2 2023 buy was Cogent Biosciences: 2,053,333 shares worth $24.3M.
  • Redmile Group added most to Immunogen Inc in Q2 2023, an estimated $114M increase.
  • Redmile Group's biggest Q2 2023 reduction was Stevanato, cutting an estimated $19.2M.
  • Redmile Group fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $102M.
  • Redmile Group's ten largest holdings make up 53% of its $2.61B portfolio in Q2 2023.
  • Redmile Group opened 6 new positions and closed 10 in Q2 2023.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.61B.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.